Latest Healthcare News

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Botanix Pharmaceuticals has secured a US$30 million debt facility from Kreos Capital, bolstering its financial position to commercialize Sofdra™ and pursue platform expansion opportunities.

Optiscan Imaging Ltd has launched InSpecta™, a cutting-edge microscopic imaging device tailored for veterinary medicine, marking its strategic entry into a booming $12 billion US market. The device promises to revolutionize diagnostics and treatment for companion animals with real-time, non-invasive imaging.

Firebrick Pharma has published its pivotal Phase 3 trial results for Nasodine nasal spray, confirming its effectiveness and safety in treating the common cold, especially when used early.

Imricor Medical Systems has secured CE Mark approval for its NorthStar Mapping System ahead of schedule, marking a pivotal shift to software-centric MRI-guided cardiac interventions across Europe and the Middle East.

EZZ Life Science has inked a three-year distribution deal with ROFA Enterprises, marking a significant step into Southeast Asia’s booming health market. The agreement guarantees at least A$21 million in sales across Thailand, Vietnam, and Singapore.

Integral Diagnostics has announced the planned retirement of CEO Dr Ian Kadish at the end of FY26, with an international search underway for his successor. The transition comes as the company focuses on integrating its recent merger with Capitol Health.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

EBR Systems has completed the first commercial US implants of its FDA-approved WiSE wireless cardiac resynchronization therapy system, marking a pivotal step toward broader market adoption and reimbursement.

Cardiex Limited has announced a fully underwritten 1-for-4 entitlement offer at $0.04 per share, aiming to raise approximately $4.1 million to advance manufacturing and scale its supply chain. The offer closes on 20 June 2025, following a recent $2.4 million placement.

Proteomics International Laboratories has expanded its Share Purchase Plan offer after receiving applications exceeding $7.5 million, significantly increasing the number of new options issued.

Apiam Animal Health announces the departure of CEO Chris Richards after nine years, appointing Bruce Dixon as interim managing director during the search for a permanent replacement.